| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.com |
| Products Intro: |
Product Name:ERK-IN-3 benzenesulfonate
CAS:2055597-39-0
Purity:详情请点击官网 Package:1 mg
|
|
| | 1H-Imidazole-4-carboxamide, N-[(1S)-2-amino-1-(3-chloro-5-fluorophenyl)ethyl]-1-[5-methyl-2-[(tetrahydro-2H-pyran-4-yl)amino]-4-pyrimidinyl]-, compd. with benzenesulfonate (1:1) Basic information |
| | 1H-Imidazole-4-carboxamide, N-[(1S)-2-amino-1-(3-chloro-5-fluorophenyl)ethyl]-1-[5-methyl-2-[(tetrahydro-2H-pyran-4-yl)amino]-4-pyrimidinyl]-, compd. with benzenesulfonate (1:1) Chemical Properties |
| storage temp. | -20°C, away from moisture | | solubility | DMSO : 320 mg/mL (506.24 mM; Need ultrasonic) |
| | 1H-Imidazole-4-carboxamide, N-[(1S)-2-amino-1-(3-chloro-5-fluorophenyl)ethyl]-1-[5-methyl-2-[(tetrahydro-2H-pyran-4-yl)amino]-4-pyrimidinyl]-, compd. with benzenesulfonate (1:1) Usage And Synthesis |
| Biological Activity | ERK-IN-3 benzenesulfonate is a potent and orally active inhibitor of ERK. ERK-IN-3 benzenesulfonate inhibits ERK1/2 with low single-digit nM IC50 values. ERK-IN-3 benzenesulfonate can be used for the research of cancers driven by RAS mutations[1].
ERK-IN-3 inhibits the phosphorylation of ERK1/2 substrates such as RSK1, FRA1, and Elk1 in various cell lines[1].ERK-IN-3 showes single-digit nanomolar antiproliferative activity that is selective for MAPK-pathway dependent cancer cell lines[1].
ERK-IN-3 (daily p.o.) inhibits tumor growth in multiple BRAF and KRAS mutant xenograft models in mice and was well tolerated at efficacious doses[1]. | | References | [1]. Sanjeeva PR, et, al. Abstract B150: ASN007, a novel oral ERK inhibitor, shows robust antitumor activity in RAS mutant cancer models. Molecular Cancer Therapeutics. 2018 Jan; 17(1). |
| | 1H-Imidazole-4-carboxamide, N-[(1S)-2-amino-1-(3-chloro-5-fluorophenyl)ethyl]-1-[5-methyl-2-[(tetrahydro-2H-pyran-4-yl)amino]-4-pyrimidinyl]-, compd. with benzenesulfonate (1:1) Preparation Products And Raw materials |
|